Advances in stem cell technology, combined with the increasing prevalence of chronic diseases, are driving rapid growth in the regenerative medicine category, which is predicted to generate $39.33 billion in revenue by 2023.

(more…)

The regenerative medicine category is predicted to generate $39.33 billion in revenue by 2023, with the fastest growth expected in cell therapy.

(more…)

“There’s a little over 1,200 clinical trials worldwide, and about half of those are in the US. Over 100 of those are in phase III, so we’re getting really close to getting more approved.”

(more…)

Project Farma experts Lesley Davis, Andrew Doppstadt, and Phil Baratta recently participated in the publication of an ISPE Guide titled, “Advanced Therapy Medicinal Products – Autologous Cell Therapy”.

(more…)

A 2018 study by Deloitte suggested that more than 2.4 million manufacturing jobs in the US would remain unfilled in 2028 because of the widening – and often generational – skills gap.

(more…)